

ASX RELEASE

15 November 2018



PARADIGM RECEIVES \$2.32m R&D TAX INCENTIVE REFUND

- **Paradigm receives R&D Tax Incentive Refund of ~ \$2.32m**
- **Strengthens capital position to \$10.5 million, following completion of tranche 2 of the successful October \$9m capital raise**
- **Assists in funding preparations for US Compassionate Use/Expanded Access and US FDA IND submissions**
- **Phase 2b OA/BMEL trial remains on track to read out top-line results mid/late December 2018**

Melbourne, 15th November, Paradigm Biopharmaceuticals Ltd (ASX: PAR) is pleased to advise that the Company has received a A\$2,318,717.48 Research & Development (R&D) Tax Incentive Refund for the 2017/2018 financial year.

Following Paradigm's successful capital raising of \$9m in October 2018, receipt of the refund further strengthens the Company's strong capital reserves. This financial position provides the Company with the funds to prepare regulatory filings with the US FDA and the Australian TGA following phase 2b read-out of results.

CEO of Paradigm, Paul Rennie commented: "Receipt of this R&D rebate is well timed with the upcoming release of the primary endpoint for the 110 patient Phase 2b osteoarthritis randomised double-blind, placebo-controlled, multi-centre clinical trial. Data QC, analysis and preparation of documents for regulatory submissions in CY2019 are currently underway for the Phase 2b OA clinical trial. The clinical trial remains on its original timeline and within the financial budget with the read-out of results in mid to late December 2018 to be a major value inflexion point for the Company".

"Our strong financial position is of significant importance as it allows us to continue to accelerate our OA programs and regulatory filings. We also intend to bring forward other value add initiatives that we are working on and we look forward to updating the market on these activities in due course."

The Australian Government R&D Tax Incentive encourages companies to engage in R&D benefiting Australia, by providing a tax offset of up to 43.5% (refundable) for eligible R&D activities.

About injectable PPS

Injectable PPS is not currently registered in Australia, but it is registered in four of the seven major global pharmaceutical markets. In those European markets, injectable PPS is registered as an antithrombotic agent. In Australia, injectable PPS for human use is not currently available for sale. Injectable PPS for human use is only available by inclusion into a Paradigm Sponsored clinical trial or via a treating physician applying for its use in patients via the TGA's SAS - Category B.

CORPORATE ENQUIRIES:

Paul Rennie

Director & CEO

Paradigm Biopharmaceuticals Ltd